COMPUGEN LTD (CGEN)
IL0010852080 - Common Stock
Overall CGEN gets a fundamental rating of 5 out of 10. We evaluated CGEN against 572 industry peers in the Biotechnology industry. CGEN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CGEN is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year CGEN was profitable.
CGEN had a positive operating cash flow in the past year.
In the past 5 years CGEN always reported negative net income.
CGEN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -8.65%, CGEN belongs to the best of the industry, outperforming 88.14% of the companies in the same industry.
Looking at the Return On Equity, with a value of -16.33%, CGEN belongs to the top of the industry, outperforming 87.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.65% | ||
| ROE | -16.33% | ||
| ROIC | N/A |
ROA(3y)-25.7%
ROA(5y)-29.88%
ROE(3y)-34.67%
ROE(5y)-40.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 73.63%, CGEN belongs to the best of the industry, outperforming 84.78% of the companies in the same industry.
CGEN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CGEN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGEN has been increased compared to 1 year ago.
CGEN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.99, we must say that CGEN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.99, CGEN perfoms like the industry average, outperforming 47.08% of the companies in the same industry.
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | -2.99 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
CGEN has a Current Ratio of 4.12. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN has a Current ratio (4.12) which is comparable to the rest of the industry.
A Quick Ratio of 4.12 indicates that CGEN has no problem at all paying its short term obligations.
CGEN has a Quick ratio (4.12) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 4.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 105.41% over the past year.
Looking at the last year, CGEN shows a very strong growth in Revenue. The Revenue has grown by 698.03%.
CGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.45% yearly.
EPS 1Y (TTM)105.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.09%
Revenue 1Y (TTM)698.03%
Revenue growth 3Y155.76%
Revenue growth 5Y13.45%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, CGEN will show a small growth in Earnings Per Share. The EPS will grow by 1.41% on average per year.
The Revenue is expected to grow by 21.40% on average over the next years. This is a very strong growth
EPS Next Y25.82%
EPS Next 2Y30.33%
EPS Next 3Y19.86%
EPS Next 5Y1.41%
Revenue Next Year129.29%
Revenue Next 2Y33.96%
Revenue Next 3Y28.17%
Revenue Next 5Y21.4%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 100.00, the valuation of CGEN can be described as expensive.
CGEN's Price/Earnings ratio is rather cheap when compared to the industry. CGEN is cheaper than 93.10% of the companies in the same industry.
CGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.28.
The Forward Price/Earnings Ratio is negative for CGEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 100 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, CGEN is valued cheaply inside the industry as 98.76% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.03 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CGEN does not grow enough to justify the current Price/Earnings ratio.
CGEN's earnings are expected to grow with 19.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.87
PEG (5Y)N/A
EPS Next 2Y30.33%
EPS Next 3Y19.86%
5. Dividend
5.1 Amount
CGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
COMPUGEN LTD
NASDAQ:CGEN (1/14/2025, 8:00:01 PM)
After market: 2.0001 +0 (+0.01%)2
+0.01 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.05%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap179.08M
Analysts86.67
Price Target5.61 (180.5%)
Short Float %1.49%
Short Ratio2.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-92.46%
Min EPS beat(2)-256.51%
Max EPS beat(2)71.58%
EPS beat(4)1
Avg EPS beat(4)-63.45%
Min EPS beat(4)-256.51%
Max EPS beat(4)71.58%
EPS beat(8)4
Avg EPS beat(8)-20.87%
EPS beat(12)8
Avg EPS beat(12)-5.93%
EPS beat(16)11
Avg EPS beat(16)-3.13%
Revenue beat(2)1
Avg Revenue beat(2)52.02%
Min Revenue beat(2)-59.62%
Max Revenue beat(2)163.65%
Revenue beat(4)2
Avg Revenue beat(4)17.01%
Min Revenue beat(4)-100%
Max Revenue beat(4)163.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10%
PT rev (3m)10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-557.14%
EPS NY rev (3m)-326.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)32.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 100 | ||
| Fwd PE | N/A | ||
| P/S | 4.19 | ||
| P/FCF | 8.03 | ||
| P/OCF | 7.98 | ||
| P/B | 3.07 | ||
| P/tB | 3.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.02
EY1%
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.25
FCFY12.45%
OCF(TTM)0.25
OCFY12.53%
SpS0.48
BVpS0.65
TBVpS0.65
PEG (NY)3.87
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.65% | ||
| ROE | -16.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.63% | ||
| FCFM | 52.17% |
ROA(3y)-25.7%
ROA(5y)-29.88%
ROE(3y)-34.67%
ROE(5y)-40.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 31.43% | ||
| Cap/Sales | 0.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 4.12 | ||
| Altman-Z | -2.99 |
F-Score5
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)67.09%
Cap/Depr(5y)48.21%
Cap/Sales(3y)3.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.09%
EPS Next Y25.82%
EPS Next 2Y30.33%
EPS Next 3Y19.86%
EPS Next 5Y1.41%
Revenue 1Y (TTM)698.03%
Revenue growth 3Y155.76%
Revenue growth 5Y13.45%
Sales Q2Q%N/A
Revenue Next Year129.29%
Revenue Next 2Y33.96%
Revenue Next 3Y28.17%
Revenue Next 5Y21.4%
EBIT growth 1Y87.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y173.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y175.29%
OCF growth 3YN/A
OCF growth 5YN/A